References
- Yang L, Ning Q, Tang SS. Recent advances and next breakthrough in immunotherapy for cancer treatment. J Immunol Res. 2022;2022:8052212. doi: 10.1155/2022/8052212
- Yang J, Wang K, Yang Z. Treatment strategies for clear cell renal cell carcinoma: past, present and future. Front Oncol. 2023;13:1133832. doi: 10.3389/fonc.2023.1133832
- Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2023 Jan;24(1): e10]. Lancet Oncol. 2022;23(9):1133–1144. doi: 10.1016/S1470-2045(22)00487-9
- Rosellini M, Marchetti A, Mollica V, et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol. 2023;20(3):133–157. doi: 10.1038/s41585-022-00676-0
- Braun DA, Bakouny Z, Hirsch L, et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18(4):199–214. doi: 10.1038/s41571-020-00455-z
- Yan XQ, Ye MJ, Zou Q, et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. [cited 2023 Oct 20];35(2):190–199. doi: 10.1016/j.annonc.2023.09.3108
- Lou B, Wei H, Yang F, et al. Preclinical characterization of GLS-010 (Zimberelimab), a novel fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Front Oncol. 2021;11:736955. doi: 10.3389/fonc.2021.736955
- Albiges L, Rodriguez LM, Kim S, et al. Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): preliminary results from an FTIH trial. J Clin Oncol. 2022;40(Suppl 16):107. doi: 10.1200/JCO.2022.40.16_suppl.107
- Voss MH, Garmezy B, Kim SH, et al. 1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC). Ann Oncol. 2023;34(suppl_2):S1013–S1031. doi: 10.1016/j.annonc.2023.09.1113
- Patwekar M, Sehar N, Patwekar F, et al. Novel immune checkpoint targets: a promising therapy for cancer treatments. Int Immunopharmacol. 2024;126:111186. doi: 10.1016/j.intimp.2023.111186
- Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927. doi: 10.1158/0008-5472.CAN-11-1620
- Niu J, Maurice-Dror C, Lee DH, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Ann Oncol. 2022;33(2):169–180. doi: 10.1016/j.annonc.2021.11.002
- Roussot N, Fumet JD, Limagne E, et al. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer. BMC Cancer. 2023;23(1):1080. doi: 10.1186/s12885-023-11534-6
- Siu LL, Wang D, Hilton J, et al. First-in-class anti-immunoglobulin-like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors [published correction appears in clin cancer res. 2022 Apr 14;28(8): 1734] [published correction appears in clin cancer res. 2022 Sep 15;28(18): 4158]. Clin Cancer Res. 2022;28(1):57–70. doi: 10.1158/1078-0432.CCR-21-2160
- Ferro M, Musi G, Marchioni M, et al. Radiogenomics in renal cancer management-current evidence and future prospects. Int J Mol Sci. 2023;24(5):4615. doi: 10.3390/ijms24054615